A new era in cystic fibrosis care: always changing and adapting.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
14
9
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
This review focuses on sharing the current and changing cystic fibrosis (CF) care model. This includes changes in CF care as a chronic disease with availability of new revolutionary, highly effective therapies as well as incorporation of shared decision-making, coproduction of care, quality improvement, telemedicine, and remote patient monitoring. Changes in the CF management, the CF patient population, and CF care team are described as well as how CF care has adapted to these changes. CF is a chronic, multisystem disease requiring a large specialized multidisciplinary care team for effective treatment. With improvements in CF care and new treatments, people with CF are living longer and healthier lives. As new issues arise, the CF team needs to adapt. This was highlighted by the introduction of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy, which targets the cellular defect in CF, the COVID-19 pandemic, which lead to the incorporation of telehealth and remote patient monitoring into the CF care model, and the partnering with people with CF and families through shared decision-making and coproduction.
Identifiants
pubmed: 37594368
doi: 10.1097/MOP.0000000000001286
pii: 00008480-990000000-00120
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-610Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
CRC Press, Walters S, Mehta A. Hodson M, Bush A, Geddes D. Epidemiology of cystic fibrosis. Cystic fibrosis 3rd ed.2007. 21–45.
Goetz D, Ren CL. Review of cystic fibrosis. Pediatr Ann 2019; 48:e154–e161.
Pereira SV, Ribeiro JD, Ribeiro AF, et al. Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools. Sci Rep 2019; 9:6234.
Davis PB. Cystic fibrosis since 1983. Am J Respir Crit Care Med 2006; 173:475–482.
Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246–259.
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891–1904.
Anderson DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938; 56:56.
Stephenson AL, Stanojevic S, Sykes J, Burgel PR. The changing epidemiology and demography of cystic fibrosis. Presse Med 2017; 46:e87–e95.
De Boeck K. Cystic fibrosis in the year 2020: a disease with a new face. Acta Paediatr 2020; 109:893–899.
Foundation CFCystic Fibrosis Foundation Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2022.
Foundation CFCystic Fibrosis Foundation Patient Registry: 2021 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2022.
Quittner AL, Abbott J, Georgiopoulos AM, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016; 71:26–34.
Cohen E, Kuo DZ, Agrawal R, et al. Children with medical complexity: an emerging population for clinical and research initiatives. Pediatrics 2011; 127:529–538.
Katkin JP, Kressly SJ, Edwards AR, et al. Guiding principles for team-based pediatric care. Pediatrics 2017; 140:1–7.
Grosse SD, Schechter MS, Kulkarni R, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics 2009; 123:407–412.
McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol 2022; 57 Suppl 1: (Suppl 1): S5–S12.
Conway S, Balfour-Lynn IM, De Rijcke K, et al. European Cystic Fibrosis Society Standards of care: framework for the Cystic Fibrosis Centre. J Cyst Fibros 2014; 13: (Suppl 1): S3–S22.
Cystic Fibrosis F. Our strategic plan. https://www.cff.org/about-us/our-strategic-plan . [Accessed 10 May 2023]
Boyle MP, Sabadosa KA, Quinton HB, et al. Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project. BMJ Qual Saf 2014; 23: (Suppl 1): i15–i22.
Marshall BC, Penland CM, Hazle L, et al. Cystic fibrosis foundation: achieving the mission. Respir Care 2009; 54:788–795. discussion 95.
Mogayzel PJ Jr, Dunitz J, Marrow LC, Hazle LA. Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Qual Saf 2014; 23: (Suppl 1): i3–i8.
Scotet V, L’Hostis C, Ferec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR Gene Discovery. Genes (Basel) 2020; 11:1–13.
Burgel PR, Burnet E, Regard L, Martin C. The changing epidemiology of cystic fibrosis: the implications for adult care. Chest 2023; 163:89–99.
Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am J Respir Crit Care Med 2020; 201:1193–1208.
Zaher A, ElSaygh J, Elsori D, et al. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus 2021; 13:e16144.
Harvey C, Weldon S, Elborn S, et al. The effect of CFTR modulators on airway infection in cystic fibrosis. Int J Mol Sci 2022; 23:
Taylor-Cousar JL. CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis. J Clin Med 2020; 9:1–11.
Dagenais RVE, Su VCH, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med 2020; 10:1–53.
Zhang L, Albon D, Jones M, Bruschwein H. Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis. Ther Adv Respir Dis 2022; 16:17534666221144211.
Kramer-Golinkoff E, Camacho A, Kramer L, Taylor-Cousar JL. A survey: understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr Pulmonol 2022; 57:1253–1261.
Friedman D, Smith BA, Bruce A, et al. Feasibility and acceptability of a CF-specific cognitive-behavioral preventive intervention for adults integrated into team-based care. Pediatr Pulmonol 2022; 57:2781–2790.
Travert G, Heeley M, Heeley A. History of newborn screening for cystic fibrosis: the early years. Int J Neonatal Screen 2020; 6:8.
Barben J, Castellani C, Munck A, et al. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros 2021; 20:810–819.
Foundation CF. LEAPP CF: leadership and education advanced practice provider fellowship program: Cystic Fibrosis Foundation. https://www.cff.org/researchers/leapp-cf-leadership-and-education-advanced-practice-provider-fellowship-program . [Accessed on 8 May 2023]
Heinz KD, Walsh A, Southern KW, et al. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database Syst Rev 2022; 6:CD013285.
Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients 2022; 14:
Foundation CF. Award for a physical therapist: Cystic Fibrosis Foundation. https://www.cff.org/researchers/award-physical-therapist . [Accessed 8 May 2023]
Foundation CF. Developing Innovative Gastroenterology Specialty Training (DIGEST) program: Cystic Fibrosis Foundation. https://www.cff.org/medical-professionals/developing-innovative-gastroenterology-specialty-training-digest-program . [Accessed 8 May 2023]
Brennan AL, Blackman SM. EnVisioning the future: endocrinology in cystic fibrosis. J Cyst Fibros 2019; 18:743–745.
Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066–1073.
Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059–1065.
Condren ME, Bradshaw MD. Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis. J Pediatr Pharmacol Ther 2013; 18:8–13.
Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663–1672.
Deeks ED. Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs 2013; 73:1595–1604.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373:220–231.
Goetz DM, Savant AP. Review of CFTR modulators 2020. Pediatr Pulmonol 2021; 56:3595–3606.
Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 2017; 377:2024–2035.
Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 2017; 377:2013–2023.
Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381:1809–1819.
Zemanick ET, Taylor-Cousar JL, Davies J, et al. A phase 3 open-label study of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med 2021; 203:1522–1532.
Goralski JL, Hoppe JE, Mall MA, et al. Phase 3 open-label clinical trial of elexacaftor/tezacaftor/ivacaftor in children aged 2 through 5 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med 2023; 208:59–67.
Kaylydeco (ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2023.
Orkambi (lumicaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2023.
Symdeco (tezacaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2023.
Trikafta (elexacaftor/tezacaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2023.
Gould MJ, Smith H, Rayment JH, et al. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. J Cyst Fibros 2022; 21:600–602.
Sadras I, Cohen-Cymberknoh M, Kerem E, et al. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators. J Cyst Fibros 2023.
McGarry ME, Gibb ER, Oates GR, Schechter MS. Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis. Paediatr Respir Rev 2022; 42:35–42.
Vagg T, Shanthikumar S, Morrissy D, et al. Telehealth and virtual health monitoring in cystic fibrosis. Curr Opin Pulm Med 2021; 27:544–553.
Dowd C, Van Citters AD, Dieni O, et al. Design and methods for understanding the state of cystic fibrosis care amid the COVID-19 pandemic. J Cyst Fibros 2021; 20: (Suppl 3): 3–8.
Prickett MH, Flume PA, Sabadosa KA, et al. Telehealth and CFTR modulators: accelerating innovative models of cystic fibrosis care. J Cyst Fibros 2022; 22:9–16.
Gifford AH, Ong T, Dowd C, et al. Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. J Cyst Fibros 2021; 20: (Suppl 3): 9–13.
Van Citters AD, Dieni O, Scalia P, et al. Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: a qualitative analysis of interviews with cystic fibrosis care team members. J Cyst Fibros 2021; 20: (Suppl 3): 23–28.
Servidio AG, Capata G, Levantino L, et al. COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients. Ital J Pediatr 2021; 47:12.
Loukou I, Moustaki M, Petrocheilou A, et al. Impact of COVID-19 lockdown on pulmonary and nutritional status in children and young adults with cystic fibrosis, in Greece. J Patient Exp 2021; 8:23743735211008295.
Hatziagorou E, Toulia I, Avramidou V, et al. Change in CF care during COVID-19 pandemic: single-center experience in a middle-income setting. Pediatr Pulmonol 2021; 56:3065–3067.
Rimbaldo K, Frayman KB, Shanthikumar S. The impact of telehealth based care on paediatric cystic fibrosis outcomes. J Cyst Fibros 2023.
Thee S, Busack LM, Mall MA, Stahl M. Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis: a mono-centre observational study. ERJ Open Res 2022; 8:
Ong T, Van Citters AD, Dowd C, et al. Remote monitoring in telehealthcare delivery across the U.S. cystic fibrosis care network. J Cyst Fibros 2021; 20: (Suppl 3): 57–63.
Paynter A, Khan U, Heltshe SL, et al. A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis. J Cyst Fibros 2022; 21:78–83.
Compton M, List R, Starheim E, et al. Home spirometry utilisation in telemedicine clinic for cystic fibrosis care during COVID-19 pandemic: a quality improvement process. BMJ Open Qual 2021; 10:
Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997; 44:681–692.
Wyatt KD, List B, Brinkman WB, et al. Shared decision making in pediatrics: a systematic review and meta-analysis. Acad Pediatr 2015; 15:573–583.
Hood-Medland EA, White AEC, Kravitz RL, Henry SG. Agenda setting and visit openings in primary care visits involving patients taking opioids for chronic pain. BMC Fam Pract 2021; 22:4.
Malone H, Biggar S, Javadpour S, et al. Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis. Cochrane Database Syst Rev 2019; 5:CD012578.
Homa K, Stevens G, Forcino R, et al. Assessing shared decision-making in cystic fibrosis care using collaboRATE: a cross-sectional study of 159 programs. J Patient Exp 2021; 8:23743735211034032.
Eckman MH, Kopras EJ, Montag-Leifling K, et al. Shared decision-making tool for self-management of home therapies for patients with cystic fibrosis. MDM Policy Pract 2017; 2:2381468317715621.
Turakhia P, Combs B. Using principles of co-production to improve patient care and enhance value. AMA J Ethics 2017; 19:1125–1131.
Cooley L, Hudson J, Potter E, et al. Clinical communication preferences in cystic fibrosis and strategies to optimize care. Pediatr Pulmonol 2020; 55:948–958.
Hempstead SE, Fredkin K, Hovater C, Naureckas ET. Patient and family participation in clinical guidelines development: the Cystic Fibrosis Foundation Experience. J Particip Med 2020; 12:e17875.
Sabadosa KA, Batalden PB. The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the coproduction of healthcare and its improvement. BMJ Qual Saf 2014; 23: (Suppl 1): i90–i94.
Ong T, Albon D, Amin RS, et al. Establishing a Cystic Fibrosis Learning Network: interventions to promote collaboration and data-driven improvement at scale. Learning Health Syst 2022.
Cystic Fibrosis F. Your CF Care Team. https://www.cff.org/managing-cf/your-cf-care-team . [Accessed 14 July 2023]